Global Human Vaccine Industry 2013-2018: Trend, Profit, and Forecast Analysis
Publish date: April 2013, more than 48 valuable figures/charts and 12 tables are provided in this report
The global vaccine industry comprises primarily human vaccine production. The annual revenue of this industry is forecast to reach an estimated $41.85 billion by 2018, with good growth over the next five years. Pfizer entered the top five player list in 2012 replacing Wyeth. Sanofi Aventis, Novartis AG, Merck Company, and GlaxoSmithKline are the other players in the top five players list.
Lucintel, a leading global management consulting and market research firm, has conducted a competitive analysis of the industry and presents its findings in “Global Human Vaccine Industry 2013-2018: Trend, Profit, and Forecast Analysis.” North America dominates this industry. India and China are rapidly growing as vaccine production hubs with strong domestic demand.
Lucintel's report gives a brief overview of the industry challenges. The global human vaccine industry is currently growing at a double-digit rate although there are numerous challenges for the major players. Competitive rivalry is moderate to high in this industry, and the threat of new entrants is low due to high capital requirements and the comprehensive, rigorous approval process. In addition, these approval processes are a major challenge for the manufacturers due to their stringent rules. Developing vaccines for adult and pediatric diseases requires high research cost. Expiration of patents is another challenge faced by vaccine manufacturers.
Despite these challenges, the industry enjoys some strong drives, as the study highlights. The global economy is recovering after the recession, and increased incomes and lower cost of vaccines have helped more infants and children become immunized, especially in the Rest of the World and Asia Pacific regions. Various countries’ national immunization programs, effectively run by nongovernmental organizations such as WHO, UNICEF, and GAVI, are a key factor in fueling growth in the vaccine industry.
This market report is an indispensable reference guide for vaccine manufacturers, researchers, people working with community health programs, investors, executives, distributors, and many more that operate in this market. To make business, investment, and strategic decisions, appropriate and useful information is needed, which is fulfilled by this market report.
This comprehensive guide from Lucintel provides readers with valuable information and the tools needed to successfully drive critical business decisions with a thorough understanding of the market’s potential. This report will save Lucintel clients hundreds of hours in personal research time on a global market and it offers significant benefits in expanding business opportunities throughout the global human vaccine industry analysis. In a fast-paced ever-changing world, business leaders need every advantage available to them in a timely manner to drive change in the market and to stay ahead of their competition. This report provides business leaders with a keen advantage in this regard by making them aware of emerging trends and demand requirements on an annual basis.
To make any investment or strategic decision, you need adequate and timely information. This market report fulfills this core need. Some of the features of this market report are:
• Industry size estimates in terms of (US $) value by regions and by segment
• Global human vaccine industry analysis annual trend (2007-2012) and forecast (2013-2018)
• Porter’s Five Force analysis
• New product launch and merger and acquisition activity in global human vaccine industry analysis
• Quarterly demand trend (Q1 2011-Q4 2012) and forecast analysis (Q1 2013-Q4 2014) for global human vaccine industry analysis
• Gross and net profit trends in the global human vaccine industry analysis
• Cost structure trend in the global as well as regional human vaccine analysis
• More than 48 valuable figures/charts and 12 tables are provided in this report